Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Simcere Pharmaceutical Group Ltd
2096Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China. Address: No. 699-18, Xuanwu Road, Nanjing, China, 210042
Analytics
Preço Alvo de Wall Street
68.51 HKDRácio P/E
–Rendimento de dividendos
2.47 %Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 2096
Análise de Dividendos 2096
Crescimento de dividendos em 5 anos
–Crescimento contínuo
1 anoTaxa de pagamento em média de 5 anos
47 %Histórico de Dividendos 2096
Avaliação de ações 2096
Relatório 2096
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |